ALK and lung cancer: Moreover, these clinical data, which do not specify any oncogenic mutation, and our invasion experiments using some lung cancer cells with different mutation including KRAS (A549), EGFR (H1650), and EML4-ALK (H2228) (Figure 3D) imply that the target therapy for COPS5 may be applicable to the lung cancer patients even with different mutation types.